Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01519063 · ClinicalTrials.gov registry record · Phase 2
Naltrexone and Memantine Effects on Alcohol Drinking Behaviors
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT01519063 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 75 participants.
The verdict
NCT01519063, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the combined effects of the study medications naltrexone and memantine on alcohol drinking behaviors.
Interventions
- DRUG Naltrexone and memantine first
- DRUG Naltrexone and Placebo first
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2012-01 |
| Est. Completion | 2017-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01519063
The ClinicalTrials.gov registry entry for NCT01519063 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Naltrexone and memantine first is the first listed.
NCT01519063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01519063 about?
NCT01519063 is a clinical study titled "Naltrexone and Memantine Effects on Alcohol Drinking Behaviors". The purpose of this study is to evaluate the combined effects of the study medications naltrexone and memantine on alcohol drinking behaviors.
What is the current status of trial NCT01519063?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2012-01. Estimated completion is 2017-05-01.
What interventions are being tested in trial NCT01519063?
The interventions under investigation include: Naltrexone and memantine first (DRUG), Naltrexone and Placebo first (DRUG).
Who is sponsoring clinical trial NCT01519063?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.